Kornimate/medical-research-clean huggingface dataset:
electro-acupuncture for obese patients with insulin resistance

Conditions: Obesity; Insulin Resistance

Summary: this clinical trial aims to evaluate the efficacy and safety of electro-acupuncture for obese patients with insulin resistance. 60 participants will be randomized and allocated to either the electro-acupuncture arm or the sham acupuncture arm.


Eligibility criteria:
inclusion criteria: * men and women aged between 21 and 65 years old * bmi ≥ 25 kg/m2 * homa-ir ≥ 2.14, (homa-ir = fasting insulin (ųu/ml)\* fasting glucose (mmol/l)/22.5) * not receiving any other weight control measures or any medical and/or drug history in the last 3 months exclusion criteria: * diabetes mellitus * treating with drugs that may affect insulin sensitivity * changes 10% of usual body weight in the previous 6 months weight * endocrine diseases, including thyroid disorder, pituitary disorder, sex gland disorder, etc. * heart diseases, including arrhythmia, heart failure, and myocardial infarction, participants with pacemakers * allergy and immunology diseases * bleeding tendency * pregnant or lactating women * impaired hepatic or renal function * stroke or unable to exercise

Keywords: electroacupuncture obesity insulin resistance
the effect of subcutaneous infusions of 3 doses of dg3173 on growth hormone levels in untreated acromegalics

Conditions: Acromegaly

Summary: this study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hgh) levels in untreated acromegalic patients in comparison to a standard dose of octreotide. in addition, the pharmacokinetic profile and the safety and tolerability of dg3173 after continuous s.c. infusion will be evaluated.


Eligibility criteria:
inclusion criteria: * men, women of non child-bearing potential, or women of child-bearing potential who either abstain from sexual intercourse, have a sterile partner or practice two medically approved, non-hormonal methods of contraception * diagnosis of acromegaly of pituitary origin * have an age-adjusted insulin-like growth factor type 1 (igf-1) concentration ≥1.2 times the upper limit of normal range on at least one measurement in the 12 months prior to screening (visit 1) and a second raised value screening * have at least one random hgh level of ≥5 μg/l in the 12 months prior to screening and a second raised value at screening * have given written informed consent * ability to comply with the requirements of the protocol for the study exclusion criteria: * previous specific treatment for acromegaly in the 12 months prior to screening, including somatostatin analogues (ssas); surgery; radiotherapy and pegvisomant * treatment with dopamine agonists in the 3 months prior to screening * uncontrolled hypertension * type i diabetes mellitus, poorly-controlled type ii diabetes mellitus (glycosylated haemoglobin \[hba1c\] ≥7.5%) and patients requiring insulin treatment * gallstones or gravel that could cause biliary obstruction * hyperprolactinaemia * participation in a clinical study within 60 days prior to screening * receipt of blood, blood products or plasma derivatives 60 days prior to screening * body mass index (bmi) below 22 or above 37 kg/m2 * pregnancy, lactation or use of any hormonal based contraceptives * concomitant intake of corticosteroids or levodopa * a history of active alcohol abuse or drug addiction * positive viral serology screening result for hepatitis b surface antigen, antibodies to hepatitis c virus, or human immunodeficiency virus type 1 and 2 * evidence or suspicion of tumour expansion * clinically significant abnormality in screening ecg in the opinion of the investigator * any clinically significant abnormal in screening laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the investigator * any disease which in the investigator's opinion would exclude the patient from the study
soluble cd23 expression in asthma patients treated with oma

Conditions: Asthma

Summary: this study involves a fda approved drug, omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. it works on ige to control the allergic reaction. we are looking at the effects on non-allergic asthma. we hope to prove that omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.

this is a 1 year placebo controlled study looking at moderate to severe asthmatics (allergic or non-allergic) who are controlled by medication. skin testing will be done to determine the allergic status, as well as a base line ige done. the omalizumab is administered by injection based on weight and ige level, (once or twice a month). at several times during the year pulmonary function test will be done, as well blood drawn for immunological assays (cd23 and fcer1 expression, th1/th2 cytokines, cd23 production). a battery of questionnaires will also determine quality of life(with asthma), psychological stress measures and parameters of clinical response.

Eligibility criteria:
inclusion criteria: moderate to severe asthmatic (based on 1997 nhlbi guidelines), controlled by medication for at least 6 months, initial ige level between 30 and 700 iu, weigh between 30 an 150 kg, otherwise healthy. exclusion criteria: smoker, uncontrolled asthma, immunotherapy in past six weeks, other diseases

Keywords: allergic non allergic
mycophenolate mofetil versus intravenous cyclophosphamide pulses in the treatment of crescentic iga nephropathy

Conditions: IGA Nephropathy

Summary: a single-center random parallel study to compare the efficacy and safety of mycophenolate mofetil versus intravenous cyclophosphamide pulses in the treatment of crescentic iga nephropathy

iga nephropathy is an immune-complex glomerulopathy that can result in capillary necrosis or extracapillary proliferation (crescents). several studies have documented a higher incidence of hypertension and nephritic-range proteinuria in patients with the crescentic form of iga nephropathy, suggesting that patients with this variant of the disease may have a worse prognosis. some studies have shown that treatment with steroids and cyclophosphamide had efficacy on reducing proteinuria and preserving renal function by healing vasculitic lesions, therefore preventing the progression of glomerular sclerosis. recent studies have also shown that mycophenolate mofetil is effective in the treatment of lupus nephritis with vasculitic lesion and small vasculitis with renal involvement. we will conduct a single-center prospective open-labeled clinical trial of 40 patients with crescentic iga nephropathy and treat them randomly with pulse intravenous cyclophosphamide or oral mycophenolate mofetil. after 12 months of treatment, we will assess the efficacy, safety, tolerability and relapse of mycophenolate mofetil compared with cyclophosphamide in the treatment of crescentic iga nephropathy.

Eligibility criteria:
inclusion criteria: patient with a diagnosis of igan without deposition of c4 and c1q, age 10-70y, sex free 1. gross hematuria or an active urine sediment 2. segmental necrotizing lesion of the capillary wall 3. cellular or fibrocellular crescents ≥ 10% 4. fibrinoid degeneration of small vessels 5. fibrin positive three or more items, with provision of criteria informed consent exclusion criteria: 1. more than four-week treatment with cytotoxic drug, such as ctx, csa and mmf, prior to enrollment 2. immune deficiency 3. serum creatinine ≥ 5.0mg/dl 4. previous malignancy 5. pregnancy 6. hepatitis 7. diabetic mellitus or obesity 8. severe infection or cvs complications 9. henoch-schonlein purpura nephritis, systemic vasculitis, sle

Keywords: crescentic iga nephropathy mycophenolate mofetil cyclophosphamide treatment
wear of enamel antagonist to two different types of monolithic zirconia monolithic zirconia

Conditions: Wear, Occlusal

Summary: the aim of the present study is to evaluate the wear of enamel opposed by newly introduced gradient monolithic zirconia compared to that of enamel opposed by full strength monolithic zirconia

the aim of the present study is to evaluate the wear of enamel opposed by newly introduced gradient monolithic zirconia compared to that of enamel opposed by full strength monolithic zirconia teeth preparation and impressions, placement and permanent cementation of the final restoration using resin cement, and optical scanning of both the restoration and the opposing tooth. follow up postoperatively after six and twelve months, and optical scanning of both the restoration and the opposing tooth.

Eligibility criteria:
inclusion criteria: - all subjects are required to be: 1. from 18-50 years old, be able to read and sign the informed consent document. 2. have no active periodontal or pulpal diseases, have teeth with good restorations. 3. psychologically and physically able to withstand conventional dental procedures. 4. patients planned for a single coverage restoration in the posterior area. 5. patients with a natural (not crowned) opposing antagonist. 6. able to return for follow-up examinations and evaluation. exclusion criteria: * patient less than 18 or more than 50 years 2. patients with severe clenching or bruxing habits. 3. patient with active resistant periodontal diseases 4. patients with poor oral hygiene and uncooperative patients 5. pregnant women 6. patients in the growth stage with partially erupted teeth 7. psychiatric problems or unrealistic expectations 8. lack of opposing dentition at the area of interest. 9. presence of dental prosthesis in the opposing arch at the area of interest.
impact of splenic artery ligation in ldlt for patients with portal hypertension

Conditions: Living Donor Liver Transplantation

Summary: in this study, the investigators aim to prove that performing splenic artery ligation in living donor liver transplantation for patients with portal hypertension is beneficial for early graft function postoperatively. the investigators will be analyzing trend of lft's (liver function tests) after surgery, time for normalization of bilirubin, inr (international normalised ratio) and decrease in ascites, morbidity, mortality, icu (intensive care unit) and total hospital stay.

liver transplantation (lt) is the principal treatment for end-stage liver diseases and selected cases of liver neoplasms . living donor liver transplantation (ldlt) serves as a sole source of liver graft in some countries that do not allow donation from deceased donors for cultural, social, or religious reasons. hyperperfusion plays an important role in liver regeneration after ldlt, but it may induce injury in the graft . after the reperfusion of a partial graft, there is a significant increase in the portal flow, but hepatic artery flow remains constant . excessive portal vein flow may induce injuries in grafts and may contribute to poor graft function. for satisfactory graft function early after lt, the portal vein pressure (pvp) value after reperfusion should be \<15 mm hg. pvp is the most important hemodynamic factor influencing the functional status of the liver and graft regeneration after lt. the use of splenic artery ligation (sal) as a simple and safe method to modulate portal flow has been reported . the investigators will evaluate that splenic artery ligation in living donor liver transplantation for patients with portal hypertension is feasible and efficient technique to improve early graft function and to decrease morbidity and hospital stay and improve outcomes .

Eligibility criteria:
inclusion criteria: * all patients undergoing living donor liver transplantation(ldlt) accepted according to hospital protocol. * patients who have portal venous pressure (pvp) \> 15 mm hg after reperfusion . exclusion criteria: * patients who have portal venous pressure (pvp) \> 15 mm hg after reperfusion. * patients who had splenectomy. * patients who have splenic artery aneurysm.
study of bg-t187 alone and in combination with other therapeutic agents in participants with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a first-in-human (fih), phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics, and preliminary antitumor activity of bg-t187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection. 2. patients must be ≥ 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place. 3. eastern cooperative oncology group (ecog) performance status ≤ 1. 4. participants with selected histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have been previously treated. 5. ≥ 1 measurable or nonmeasurable lesion as assessed by recist v1.1. for phase 1a part a; ≥ 1 measurable lesion per recist v1.1. for phase 1a part b and phase 1b. 6. adequate organ function. exclusion criteria: 1. prior severe allergic reactions or hypersensitivity to the active ingredient and excipients of bg-t187 or other monoclonal antibodies. 2. spinal cord compression, active leptomeningeal disease, or uncontrolled, untreated brain metastasis. 3. any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast). 4. history of ild or noninfectious pneumonitis requiring steroids or other immune suppressive agents ≤ 2 years before the first dose of the study drug, or with current ild/noninfectious pneumonitis, or where suspected ild/noninfectious pneumonitis cannot be ruled out by imaging during screening. 5. uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence ≤14 days after intervention). 6. active hepatitis c. 7. infection (including tuberculosis infection, or other) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s). note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: advanced solid tumors first-in-human bg-t187 egfr c-met
to compare the incidence of post between a taperguard ett and cylindrical-shaped ett under high cuff pressure

Conditions: Postoperative Complications

Summary: postoperative sore throat (post) is supposed to be the most frequently occurred respiratory complication related to endotracheal intubation .whether the new type of ett(taperguard ett) to decrease or to increase the complications of general anesthesia compared with cylindrical-shaped ett is still unknown .in this study ,we will compare the different incidence of complications following general anesthesia between taperguard ett and cylindrical-shaped ett under high endotracheal tube cuff pressure.

background:postoperative sore throat (post) is supposed to be the most frequently occurred respiratory complication related to endotracheal intubation .endotracheal tube size ,airway manipulation ,patients position et al. have been recognized as the factors affecting postoperative sore throat .controversy in respect of the relationship between the cuff design and post is still existed. whether the new type of ett (taperguard ett) to decrease or to increase the complications of general anesthesia compared with cylindrical-shaped ett is still unknown .in this study ,we will compare the different incidence of complications following general anesthesia between taperguard ett and cylindrical-shaped ett under high endotracheal tube cuff pressure. methods:patients undergoing elective non-throat and non-neck surgery were randomly allocated to receive either a taperguard ett(group t) or cylindrical-shaped ett ( group c).patients received general anesthesia with different endotracheal tubes .recoil of inflation syringe plunger was used to inflate the cuff. in the study , the cuff pressures of the endotracheal tube were recorded by a calibrated cuff manometer at two time: when the intubation was complited and before endotracheal tube was removed. the incidence and severity of postoperative sore throat(post),hoarseness, cough were collected by a single investigator blinded to the experiment at 0, 1,6, 12, and 24 hours post-operation.

Eligibility criteria:
inclusion criteria: * general anesthesia surgery aged 18 to 75 years asa classⅰ or ⅱ undergoing elective non-throat and non-neck surgery under generalanesthesia intubation timemore than two hours bmi≤30 kg／m2 exclusion criteria: * patients with ahistory of preoperative sore throat known airway disease and difficult intubation more than one attempt at intubation mallampati grade 3 to 4 cormack-lehane grade3 to 4 bmi \>35 kg/m2 those have an operation with the lateral flank or prone position

Keywords: postoperative sore throat,anesthesia
comparison of sevoflurane, propofol, and sevoflurane plus propofol for maintenance of anaesthesia

Conditions: Laparoscopic Surgery; Hysteroscopic Surgery

Summary: postoperative pain may be affected by general anaesthetics. the effect of propofol and sevoflurane on postoperative pain in chinese female patients has not been demonstrated before. this study compared the postoperative pain score in patients under general anaesthesia maintained with propofol,sevoflurane, or sevoflurane+propofol.

after approval from the institute's ethics committee, this study was conducted at tongji hospital, a general university teaching hospital with 2500 beds in wuhan, china.the study consisted of female patients, american society of anaesthesiologists physical status (asa-ps) i or ii, suffering from infertilities, and undergoing selective gynaecological laparoscopic and hysteroscopic surgery. all the patients were randomly assigned to receive propofol,sevoflurane,or sevoflurane+propofol for anaesthesia maintenance. the primary outcome measure was the level of postoperative pain assessed by numerical analogue scale (nas) at rest 0.5 hour after the operation. the secondary outcomes were postoperative pain assessed by numerical analogue scale (nas) at rest 1 and 24 hour after the operation, the incidence of postoperative nausea and vomiting, the incidence of shiver, and quality of recovery determined by qor40 in the first 24 h after surgery.

Eligibility criteria:
inclusion criteria: * asa physical status class 1 or 2 * aged \>=18 years and =\<40 years old * suffering from infertilities * under elective gynaecological laparoscopic and hysteroscopic surgery exclusion criteria: * asa-ps\>=iii * aged under 18 yrs or above 40 yrs old * body mass index (bmi) \>30 * respiratory or neurologic disease * chronic antidepressants and anticonvulsant drugs * chronic analgesics intake * a known allergy to the drugs being used * history of substance abuse * participating in the investigation of another experimental agent * participating in the investigation of another study

Keywords: postoperative pain sevoflurane propofol female elective gynaecological surgery laparoscopic and hysteroscopic surgery female patients undergoing elective laparoscopic and hysteroscopic surgery
therapeutically alternatives in ventilator-induced diaphragm dysfunction critically ill patients

Conditions: Ventilator-Induced Diaphragmatic Dysfunction

Summary: the study is a prospective experimental study on adult patients admitted to the critical care department in qasr al-ainy. this study is conducted prospectively to assess the efficiency of trigger sensitivity adjustment on patients with ventilator-induced diaphragmatic dysfunction (vidd).

the study is a prospective experimental study on adult patients admitted to the critical care department in qasr al-ainy. this study is conducted prospectively to assess the efficiency of trigger sensitivity adjustment on patients with ventilator-induced diaphragmatic dysfunction (vidd).1. flow trigger: this type of trigger responds to the gas flow during inspiration. a flow trigger measures the rate of change of flow as the patient begins to inhale. when the flow reaches a certain threshold, the ventilator is triggered to deliver a breath. 1. laboratory investigations: arterial blood gases (abg):- (ph, pco2, hco3, and po2) after the session. 2. ventilator parameters:( a) minute ventilation, b) tidal volume, c) rapid shallow breathing index, d) negative inspiratory force (nif) will be measured pre and post-treatment

Eligibility criteria:
age (years) weight (kg) height (cm) bmi (kg/m²) inclusion criteria: * patients who had undergone mv for 48 hours or more in a controlled mode. * patients could not generate maximum inspiratory pressure of more than 15 mbar * patients had diaphragmatic excursion less than 3 cm. (normal level from 3 to 5 cm.)(it can increase in a condition person to 7-8 cm). * patients had a diaphragmatic thickness fraction of less than 30% exclusion criteria: * patients with comorbidities interfering and compromising weaning like cardiac arrhythmia, pericardial effusion, congestive heart failure, or unstable acute coronary syndrome. * patients who had inadequate training performance of the inspiratory muscle such as those having myopathy or neuropathy. * patients hemodynamically unstable. * patients who had a major neurological deficit. * sedated patients.

Keywords: trigger sensitivity diaphragmatic dysfunction mechanical ventilator minute ventilation tidal volume
establishment of pronephro aki (ngal) cut off value for risk assessment of moderate to severe acute kidney injury in adults

Conditions: Acute Kidney Injury

Summary: the purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. this is to assess the performance of the pronephro aki (ngal) assay (lab test) as an aid to identify patients at risk for acute kidney injury.


Eligibility criteria:
inclusion criteria: male and females ≥ 22 years of age. subjects must be admitted to an intensive care unit and must have a urine sample collected within 24 hours of icu admission. subjects must have at least one of the following leading to admission to the icu, or occurring within 24 hours of admission to the icu: * vasoactive medication administration * mechanical ventilation * hypoxemia requiring oxygen support therapy including bilevel positive airway pressure (bipap) and high flow nasal canula * mean arterial pressure (map) less than 60 (within 12 hrs. of icu admission only) * serum lactate greater than 2.5 mmol/l * history of solid organ transplantation, renal transplantation included only if more than 3 months prior * history of bone marrow transplantation subject with signed informed consent. exclusion criteria: special populations including pregnant and lactating women, prisoners, or institutionalized individuals. subjects receiving kidney replacement therapy in the first 24 hours of icu admission. subjects diagnosed with active urinary tract infection per institute standard of care at the time of ngal sampling. subjects with a known history of chronic kidney disease stages 4 and 5 as evidenced by a pre-enrollment estimated gfr of less than 30 ml/min/1.73m2 and under the care of a nephrologist. subjects with any known urothelial, urological or kidney malignancies. subjects that have had any urologic procedure or urologic surgery immediately prior to admission to the icu. subjects that have had surgical nephrectomy less than 3 months prior to admission. subjects that have been previously enrolled in this study. subjects that do not have a baseline scr within 6 months prior to icu admission available. subjects that did not sign the informed consent. subjects enrolled in an interventional pharmaceutical or device clinical trial at time of icu admission

Keywords: ngal icu adult